Medicxi Ventures

About The Fund

Medicxi Ventures is a life sciences-focused investment firm that operates primarily in the BioTech, Medical Devices (& Hospital Services), and Pharmaceutical (& Medicine) sectors. Medicxi was originally established within Index Ventures—a recognized international venture capital firm with locations in London, San Francisco, Geneva, and Jersey. The firm emerged from Index Ventures when life sciences practice leader Francesco De Rubertis and partners Kevin Johnson, Michèle Ollier, and David Grainger decided to concentrate exclusively on life sciences investments. Medicxi has a history of raising twelve different funds through its former association with Index Ventures, leveraging separate investment teams for technology and life sciences. Now, as a standalone entity, they continue to build on this legacy, specializing in early-stage and seed investments. Medicxi's investment strategy revolves around providing financial resources within a range of 7 million to 30 million. The firm's approach is underpinned by a deep scientific and operational expertise that allows them to identify, evaluate, and foster innovative companies that could potentially transform the healthcare landscape. Medicxi operates with the conviction that breakthrough science and patient-oriented solutions form the cornerstone of successful therapeutic ventures. By financing and supporting cutting-edge research and development, they aim to contribute to the advancement of medical science and the enhancement of health outcomes worldwide. The fund is headquartered in the UK, which remains a hub of activity and innovation in the life sciences sector, serving as a bridge between European and global biotechnology markets.